Literature DB >> 2730286

Tumor inhibiting properties of stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-compl exe s, Part I: Synthesis.

M Jennerwein, R Gust, R Müller, H Schönenberger, J Engel, M R Berger, D Schmähl, S Seeber, R Osieka, G Atassi.   

Abstract

The synthesis of the stereoisomeric 1,2-bis(3-hydroxyphenyl)ethylenediamines (1-4) from meso-1,2-bis(2-hydroxyphenyl)ethylenediamine and 3-methoxybenzaldehyde by a diaza-Cope-rearrangement and subsequent ether cleavage with BBr3 and their conversion into the [1,2-bis(3-hydroxyphenyl)ethylenediamine]dichloroplatinum(II)-complexes with K2PtCl4 (1-PtCl2 - 4-PtCl2) is described.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2730286     DOI： 10.1002/ardp.19893220107

Source DB:  PubMed          Journal:  Arch Pharm (Weinheim)        ISSN： 0365-6233            Impact factor:   3.751


  3 in total

1.  [1,2-Bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer. II. Synthesis and preliminary testing of the enantiomeric complexes.

Authors:  G Bernhardt; R Gust; H Reile; H D vom Orde; R Müller; C Keller; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Tumor-inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. V. Synthesis and evaluation of enantiomeric [1,2-bis-(4-fluorophenyl)ethylenediamine]dichloroplatinum(II) complexes.

Authors:  H D vom Orde; H Reile; R Müller; R Gust; G Bernhardt; T Spruss; H Schönenberger; T Burgemeister; A Mannschreck
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

3.  [DL-1,2-bis(2-hydroxyphenyl)ethylenediamine]dichloroplatinum(II), a new compound for the therapy of ovarian cancer.

Authors:  R Müller; R Gust; G Bernhardt; C Keller; H Schönenberger; S Seeber; R Osieka; A Eastman; M Jennerwein
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.